Research statistics
Semaglutide research: publications and trials
At a glance
Publications, all years
4,916
Since 2012
Publications in 2026 so far
1,655
Through November 8, 2026
Human clinical research
40.1%
1,955 of 4,875 classified
Registered clinical trials
654
ClinicalTrials.gov
Randomized controlled trials
367
Publications reporting an RCT in people
Systematic reviews and meta-analyses
443
Preclinical studies
14.4%
448 animal · 87 in vitro · 165 computational
Records that only mention it
637
Not counted above
Status in the library: FDA-approved. Groups: GLP-1 receptor agonists. 41 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Semaglutide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2012 | 0 | 0 | 1 | 0 | 1 |
| 2013 | 0 | 0 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 | 1 | 3 |
| 2015 | 2 | 1 | 0 | 0 | 3 |
| 2016 | 2 | 0 | 6 | 2 | 10 |
| 2017 | 13 | 1 | 27 | 15 | 56 |
| 2018 | 22 | 9 | 54 | 9 | 94 |
| 2019 | 26 | 13 | 35 | 20 | 94 |
| 2020 | 32 | 19 | 56 | 12 | 119 |
| 2021 | 55 | 27 | 59 | 46 | 187 |
| 2022 | 76 | 50 | 74 | 21 | 221 |
| 2023 | 147 | 63 | 80 | 80 | 370 |
| 2024 | 327 | 113 | 200 | 174 | 814 |
| 2025 | 559 | 173 | 304 | 252 | 1,288 |
| 2026 (to date) | 694 | 230 | 528 | 203 | 1,655 |
Study types
| Observational human study | 1,153 |
|---|---|
| Review | 983 |
| Editorial, letter or other | 778 |
| Animal study | 448 |
| Randomized controlled trial | 367 |
| Case report | 323 |
| Meta-analysis | 254 |
| Systematic review | 189 |
| Computational study | 165 |
| Other clinical trial | 112 |
| In vitro study | 87 |
| Not yet classified | 41 |
| Guideline or consensus | 16 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 3,327 |
|---|---|
| Obesity and weight management | 2,050 |
| Endocrinology | 1,877 |
| Cardiovascular | 934 |
| Gastrointestinal | 569 |
| Neurological and mental health | 513 |
| Immune system | 226 |
| Reproductive and sexual health | 202 |
| Musculoskeletal | 153 |
| Oncology | 105 |
| Cognitive health | 96 |
| Dermatology | 82 |
Registered clinical trials
102 of 281 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 317 · Recruiting: 133 · Not yet recruiting: 80 · Active, not recruiting: 58 · Unknown status: 35 · Enrolling by invitation: 11 · Withdrawn: 11 · Terminated: 8 · Suspended: 1
Early phase 1: 5 · Phase not applicable: 134 · Phase 1: 116 · Phase 1 / Phase 2: 8 · Phase 2: 112 · Phase 2 / Phase 3: 12 · Phase 3: 159 · Phase 4: 108
The 50 most recently started of 654 trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times
PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis.
Heart rhythm · October 26, 2026 · Meta-analysis · cited 0 times
PMID 42933519 · DOI 10.1016/j.hrthm.2026.10.052 · Reviews and meta-analyses
- Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis.
European journal of clinical pharmacology · October 24, 2026 · Meta-analysis · cited 0 times
PMID 42920001 · DOI 10.1007/s00228-026-04206-4 · Reviews and meta-analyses
- CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.
Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access
PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis.
Medicine · October 1, 2026 · Meta-analysis · cited 0 times · open access
PMID 42937793 · DOI 10.1097/md.0000000000051306 · Reviews and meta-analyses
- Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Clinical obesity · October 1, 2026 · Meta-analysis · cited 0 times · open access
PMID 42584177 · DOI 10.1111/cob.70105 · Reviews and meta-analyses
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Clinical obesity · October 1, 2026 · Meta-analysis · cited 0 times · open access
PMID 42670242 · DOI 10.1111/cob.70111 · Reviews and meta-analyses
- Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.
International journal of obesity (2005) · September 28, 2026 · Meta-analysis · cited 0 times · open access
PMID 42806056 · DOI 10.1038/s41366-026-02229-6 · Reviews and meta-analyses
- GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.
Drugs · September 26, 2026 · Meta-analysis · cited 0 times
PMID 42791433 · DOI 10.1007/s40265-026-02380-4 · Reviews and meta-analyses
- Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.
Diabetes, obesity & metabolism · September 21, 2026 · Meta-analysis · cited 0 times · open access
PMID 42768849 · DOI 10.1111/dom.71358 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine · September 15, 2016 · Randomized controlled trial · cited 6,867 times · open access
PMID 27633186 · DOI 10.1056/nejmoa1607141 · Human clinical research
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine · February 10, 2021 · Randomized controlled trial · cited 5,142 times · open access
PMID 33567185 · DOI 10.1056/nejmoa2032183 · Human clinical research
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The New England journal of medicine · November 11, 2023 · Randomized controlled trial · cited 3,168 times · open access
PMID 37952131 · DOI 10.1056/nejmoa2307563 · Human clinical research
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
The New England journal of medicine · June 25, 2021 · Randomized controlled trial · cited 2,072 times · open access
PMID 34170647 · DOI 10.1056/nejmoa2107519 · Human clinical research
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
The New England journal of medicine · November 13, 2020 · Randomized controlled trial · cited 2,024 times · open access
PMID 33185364 · DOI 10.1056/nejmoa2028395 · Human clinical research
Latest publications
- GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.
GeroScience · November 4, 2026 · In vitro study · cited 0 times
PMID 42980901 · DOI 10.1007/s11357-026-02625-w · In vitro studies
- Investigating GLP-1 sourcing preferences on social media and motivations for use: Survey with choice-based conjoint (CBC) exercise.
PloS one · November 4, 2026 · Observational human study · cited 0 times
PMID 42981240 · DOI 10.1371/journal.pone.0359937 · Human clinical research
- GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: A Review.
Cardiology in review · November 3, 2026 · Review · cited 0 times
PMID 42975978 · DOI 10.1097/crd.0000000000001527 · Reviews and meta-analyses
- Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process.
Archives of disease in childhood · November 3, 2026 · Guideline or consensus · cited 0 times
PMID 42977490 · DOI 10.1136/archdischild-2026-330728 · Commentary and other
- Digital Augmentation of Glucagon-Like Peptide-1 for Obesity Management: Retrospective Study.
Journal of medical Internet research · November 3, 2026 · Observational human study · cited 0 times
PMID 42976342 · DOI 10.2196/100728 · Human clinical research
- Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial.
Diabetes, obesity & metabolism · November 3, 2026 · Other clinical trial · cited 0 times
PMID 42977539 · DOI 10.1111/dom.71407 · Human clinical research
- Semaglutide, Tirzepatide and Clinically Recorded Alcohol-Related Outcomes in Type 2 Diabetes: A Target Trial Emulation.
Diabetes, obesity & metabolism · November 3, 2026 · Observational human study · cited 0 times
PMID 42977546 · DOI 10.1111/dom.71470 · Human clinical research
- Next-generation incretin therapeutics for polyendocrine metabolic ovarian syndrome: navigating current pipeline and clinical considerations.
Expert opinion on pharmacotherapy · November 3, 2026 · Review · cited 0 times
PMID 42978208 · DOI 10.1080/14656566.2026.2760042 · Reviews and meta-analyses
- [New oral anti-obesity drugs: the future or second choice?]
Innere Medizin (Heidelberg, Germany) · November 3, 2026 · Review · cited 0 times
PMID 42977781 · DOI 10.1007/s00108-026-02204-3 · Reviews and meta-analyses
- Bariatric Surgery as a Rescue Strategy After Semaglutide or Tirzepatide.
Annals of surgery · November 3, 2026 · Observational human study · cited 0 times
PMID 42972633 · DOI 10.1097/sla.0000000000007251 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Kayshild; NN9535; NN9536; NN9924; Ozempic; Rybelsus; Semaglutide; Wegovy
((TITLE_ABS:"Kayshild" OR CHEM:"Kayshild") OR (TITLE_ABS:"NN9535" OR CHEM:"NN9535" OR TITLE_ABS:"NN 9535" OR CHEM:"NN 9535") OR (TITLE_ABS:"NN9536" OR CHEM:"NN9536" OR TITLE_ABS:"NN 9536" OR CHEM:"NN 9536") OR (TITLE_ABS:"NN9924" OR CHEM:"NN9924" OR TITLE_ABS:"NN 9924" OR CHEM:"NN 9924") OR (TITLE_ABS:"Ozempic" OR CHEM:"Ozempic") OR (TITLE_ABS:"Rybelsus" OR CHEM:"Rybelsus") OR (TITLE_ABS:"Semaglutide" OR CHEM:"Semaglutide") OR (TITLE_ABS:"Wegovy" OR CHEM:"Wegovy")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 9). Semaglutide research statistics (Version weekly-2026-11-08) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/semaglutide